Streetbeat News

Revenues

HRMY

Harmony Biosciences has reiterated its full-year 2024 net product revenue guidance, expecting revenue between $700 million and $720 million.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 11:33 am

HD

Jim Cramer expresses confidence in Home Depot's resilience and potential for success despite Federal Reserve's interest rate decisions. He highlights Home Depot's dual nature as a secular and cyclical stock, supported by trends like housing shortages and aging homes. Despite recent performance scrutiny and revenue shortfalls, Cramer believes Home Depot will continue to thrive.

Portfolio Pulse from Benzinga Neuro

October 29, 2024 | 11:32 am

HUBB

Hubbell reported Q3 2024 earnings per share of $4.49, surpassing the analyst estimate of $4.45, marking a 13.67% increase from last year. However, sales were $1.44 billion, missing the $1.48 billion estimate, though up 4.80% from last year.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 11:31 am

WKSP

Worksport Ltd (NASDAQ:WKSP) has announced significant growth in its B2B sales, driven by a 200% increase in dealer account sales and a successful pre-order campaign for its AL4 Premium Tonneau Cover. The company is expanding its dealer network across the USA and Canada, with a notable 31% conversion rate from retail display units. Worksport is also entering new markets, including Puerto Rico, and anticipates strong demand for its products.

Portfolio Pulse from Anusuya Lahiri

October 29, 2024 | 11:30 am

WKSP

Worksport has announced a significant growth in its B2B sales, exceeding 200%. The company has also initiated a pre-order campaign for its new AL4 Tonneau Cover.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 11:30 am

SXI

Standex International Corporation anticipates higher revenue and operating margins for Q2, driven by increased sales and investments. The recent acquisition of Amran/Narayan Group is expected to positively impact earnings per share in fiscal Q2 2025.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 11:26 am

GLYC

GlycoMimetics is set to merge with Crescent Biopharma, securing $200M funding to advance their oncology pipeline. The combined company will focus on Crescent's biologics for solid tumors, with key programs including CR-001, CR-002, and CR-003. The funding is expected to support operations through 2027.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 11:25 am

SXI

Standex International reported Q1 2025 earnings per share of $1.71, meeting analyst expectations, but sales of $170.50 million missed the $181.39 million estimate. This represents a decrease in both earnings and sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 11:23 am

HAYW

Hayward Holdings has updated its FY24 net sales guidance to a range of $1.020 billion to $1.04 billion, slightly adjusting the lower end from the previous range of $1.010 billion to $1.04 billion. This aligns closely with the market estimate of $1.02 billion.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 11:22 am

HAYW

Hayward Holdings reported Q3 2024 earnings per share of $0.11, surpassing the analyst estimate of $0.10. The company's sales reached $227.569 million, exceeding the expected $223.875 million and marking a 3.30% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 11:18 am